WO2005046695A1 - Injection vitamin b complex for treatment of non specific vaginitis (bacterial vaginitis) - Google Patents
Injection vitamin b complex for treatment of non specific vaginitis (bacterial vaginitis) Download PDFInfo
- Publication number
- WO2005046695A1 WO2005046695A1 PCT/KE2004/000008 KE2004000008W WO2005046695A1 WO 2005046695 A1 WO2005046695 A1 WO 2005046695A1 KE 2004000008 W KE2004000008 W KE 2004000008W WO 2005046695 A1 WO2005046695 A1 WO 2005046695A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- complex
- vaginitis
- injection
- vitamin
- yeast
- Prior art date
Links
- 208000004926 Bacterial Vaginosis Diseases 0.000 title claims abstract description 15
- 235000019156 vitamin B Nutrition 0.000 title claims abstract description 14
- 239000011720 vitamin B Substances 0.000 title claims abstract description 14
- 238000002347 injection Methods 0.000 title claims abstract description 11
- 239000007924 injection Substances 0.000 title claims abstract description 11
- 229940046001 vitamin b complex Drugs 0.000 title claims abstract description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 13
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 7
- 210000001215 vagina Anatomy 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 239000002151 riboflavin Substances 0.000 claims abstract description 4
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229960003966 nicotinamide Drugs 0.000 claims abstract description 3
- 239000011570 nicotinamide Substances 0.000 claims abstract description 3
- 235000005152 nicotinamide Nutrition 0.000 claims abstract description 3
- 229960002477 riboflavin Drugs 0.000 claims abstract description 3
- 235000019192 riboflavin Nutrition 0.000 claims abstract description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract description 3
- 239000011703 D-panthenol Substances 0.000 claims abstract 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims abstract 2
- 235000004866 D-panthenol Nutrition 0.000 claims abstract 2
- 229960003949 dexpanthenol Drugs 0.000 claims abstract 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 2
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 2
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 2
- 229960000344 thiamine hydrochloride Drugs 0.000 claims description 2
- 235000019190 thiamine hydrochloride Nutrition 0.000 claims description 2
- 239000011747 thiamine hydrochloride Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 5
- 210000003756 cervix mucus Anatomy 0.000 abstract description 3
- 206010046901 vaginal discharge Diseases 0.000 abstract description 3
- 208000003251 Pruritus Diseases 0.000 abstract description 2
- 230000007803 itching Effects 0.000 abstract description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 abstract description 2
- 210000003905 vulva Anatomy 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 2
- 239000008215 water for injection Substances 0.000 abstract description 2
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 abstract 3
- 235000019445 benzyl alcohol Nutrition 0.000 abstract 1
- 229940011671 vitamin b6 Drugs 0.000 abstract 1
- 235000020985 whole grains Nutrition 0.000 description 4
- 229930003270 Vitamin B Natural products 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- QBQNMIPDPJEZHR-UHFFFAOYSA-N 4-[(4-hydroxyphenyl)methoxymethyl]-2-[(4-hydroxyphenyl)methyl]phenol Chemical compound C1=CC(O)=CC=C1COCC1=CC=C(O)C(CC=2C=CC(O)=CC=2)=C1 QBQNMIPDPJEZHR-UHFFFAOYSA-N 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 240000004713 Pisum sativum Species 0.000 description 2
- 235000010582 Pisum sativum Nutrition 0.000 description 2
- 208000035415 Reinfection Diseases 0.000 description 2
- 208000037009 Vaginitis bacterial Diseases 0.000 description 2
- 230000001857 anti-mycotic effect Effects 0.000 description 2
- 239000002543 antimycotic Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 235000014571 nuts Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- XKTORWGDEJVTRL-OGFXRTJISA-N C(C1=CC=CC=C1)O.OCCCNC([C@@H](O)C(C)(C)CO)=O Chemical compound C(C1=CC=CC=C1)O.OCCCNC([C@@H](O)C(C)(C)CO)=O XKTORWGDEJVTRL-OGFXRTJISA-N 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 206010048461 Genital infection Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- -1 Nystatia Chemical compound 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- 206010064899 Vulvovaginal mycotic infection Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229960005074 butoconazole Drugs 0.000 description 1
- SWLMUYACZKCSHZ-UHFFFAOYSA-N butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
Definitions
- Non specific vaginitis is the most common lower genital infection worldwide, It is associated with alteration of normal vaginal flora rather than infection caused by specific microorganism, The condition is characterized by a decreased concentration of lacto-bacillus, an increased numbers of gardneralla vaginalis and excessive yeast cells but no candidiasis. The condition remains to be very irritating and stressful to many women worldwide, Non- specific vaginitis present with severe vulva itching, profuse vaginal discharge and vaginal Ph >4,5. Medicaments that have been used for the condition include, Gential Viloet, Boric acid, Nystatia, clotrimazole, Butoconazole, miconazole, econazole and ketaconazole.
- the drugs preparations that have been used include vaginal pessaries, oral tablets and topical creams, Metrodazole has also been used to combat the increased gram- negative micro- organisms in the vagina.
- Niacinamide, D-panthenol Benzyl-Alcohol in water for injection Niacinamide, D-panthenol Benzyl-Alcohol in water for injection.
- the natural sources of the vitamin B complex B are:-
- vit B is whole grains, nuts, eggs, yeast, meats, milk, beans, peas, and sweet potatoes.
- Panthothenic acid - organ meats and whole grain cereals® 5.
- Vit B Complex which is an extract from yeast
- Vit B Complex was given to inhibit the production of yeast in the vagina. More than 30 patients with clinical presentation of B.V, have been treated using vitamin B complex.
- Non-Specific vaginities is yeast related problem rather than bacterial infection and that it is not an external problem but an internal problem in individual patient which is yet to be established.
- injection B complex relieves the symptoms of Non specific vaginitis though the specific B. vitamin involved is also yet to be established. I therefore believe that with more research on Inj. Vitamin B complex; a light is blinking for management of non- specific vaginitis at the end of the tunnel.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates a medicament of injection B. Complex used for treating bacterial vaginitis. Though it is not determined the exact B vitamin involved, injecting a patient with lee of injection B complex inhibit the production of yeast in the vagina and thus ceasation of the itching of vulva and excessive vaginal discharge. The Vitamin B complex injection used is composed of Thiamine Hcl, Riboflavin, Pyridoxin Hcl, Niacinamide D-panthenol and Benzyl alcohol in water for injection.
Description
Injection Vitamin B. Complex for treatment of Non Specific Vaginitis (Bacteria Vaginitis)
Non specific vaginitis is the most common lower genital infection worldwide, It is associated with alteration of normal vaginal flora rather than infection caused by specific microorganism, The condition is characterized by a decreased concentration of lacto-bacillus, an increased numbers of gardneralla vaginalis and excessive yeast cells but no candidiasis. The condition remains to be very irritating and stressful to many women worldwide, Non- specific vaginitis present with severe vulva itching, profuse vaginal discharge and vaginal Ph >4,5. Medicaments that have been used for the condition include, Gential Viloet, Boric acid, Nystatia, clotrimazole, Butoconazole, miconazole, econazole and ketaconazole. The drugs preparations that have been used include vaginal pessaries, oral tablets and topical creams, Metrodazole has also been used to combat the increased gram- negative micro- organisms in the vagina. A • combination of vaginal tabs, oral tabs and creams have been used in hope of clearing gastrol intestinal tract of fungal infection to avoid re-infection of the genital tract®), Majority of the patient get relieved of the symptoms in the course of treatment but the symptom reappears immediately or sooner after stopping medication. The etiology of Bacterial vaginitis remains enigmatic and majority of researches agree that though failure of therapy and reccurence of vaginal yeast infection, there is poor understanding of the problem <lAW> Injection vitamin B, complex used in the new management of Bacterial vaginosis is composed of Thiamine Hydrochloride, Riboflavin, PyridoxineHydrochloride,
Niacinamide, D-panthenol Benzyl-Alcohol in water for injection. The natural sources of the vitamin B complex B are:-
1. Thaimine (vit B,) is whole grains, nuts, eggs, yeast, meats, milk, beans, peas, and sweet potatoes.
2. Riboflavin (vit B2) _ milk, cheese, eggs, organ meat, whole grains, green vegetables, peas, been, dried yeast.
3. Pyridoxine (vit B6) - wheat germ, whole grains, nuts, (peanuts, walnut), soya beans and yeast.
4. Niacianamide (Vit B3) _ yeast, liver,
5. Panthothenic acid - organ meats and whole grain cereals®).
All these vitamins in injection Vitamin B complex have the yeast component as a source. Bacterial Vaginitis have the presentation of excessive yeast cells. Therefore the B vitamins being extracts from yeast was used to combat the excessive yeast production in the vagina.
Case History
A patient -who had bacterial vaginitis for over 10 years had always thought that her husband used to re-infect her after treatment. The husband went abroad for studies for 3 years. In his absence the patient was treated using several antimycotics and antibiotics but re-infection reccurred immediately after end of drug use. The patient went to the extent of discarding her old panties and got new ones with commencement of treatment, > On laboratory examination of the vaginal discharge no Candida albican was seen except excessive yeast cells, Yeast is a normal flora in the vagina but can become pathogenic in unfavourable condition e.g. pregnancy, prolonged antibiotic use, etc. I observed that the problem was not external but internal and that it responded to antimycotics when in use, I therefore came up with ideas that the problem was the yeast infection rather than the bacterial flora, The theory used here is that one of "Dawa ya moto ni moto" which means that "the treatment of fire is fire" which was also observed by Ludwig Harbelandt that extracts from the ovaries given to women inhibited the normal hormone production and thus contraception®,
I then gave injection Vitamin B complex 1 cc alternate 3 days which gave tremendous affects, Vit B Complex (which is an extract from yeast) was given to inhibit the production of yeast in the vagina. More than 30 patients with clinical presentation of B.V, have been treated using vitamin B complex.
Conclusion:
Non-Specific vaginities is yeast related problem rather than bacterial infection and that it is not an external problem but an internal problem in individual patient which is yet to be established. The use of injection B complex relieves the symptoms of Non specific vaginitis though the specific B. vitamin involved is also yet to be established. I therefore believe that with more research on Inj. Vitamin B complex; a light is blinking for management of non- specific vaginitis at the end of the tunnel.
Referees:
1. The future of bacterial vaginosis related research Taylor Robinson Int. J. Gycaecol obstet Nov. 1999 67 supp 1 pg. S35 - 8
2. Richard L, Sweet & Ronald S, Gibs Disease of the female Genital tract Pg 216 - 247
3. Pitkin/Zlatkin 1979 year book of obstetrics & Gynaecology P.g 258 - 260
4. Pitkin/Zlatkin 1984 Yearbook of obstetrics & Gynaecology P,g 337 - 339
5. Ronald L. Klanman Hormonal Contraceptive 1992 P.g ll
6. Alvin K. Myrtle P. Matejski Nursing Pharmacology An Integrated Approach to Drug therapy and Nursing Practice, Pg. 846 - 851
Claims
1. The use of injection Vitamin B Complex comprising of Thiamine Hydrochloride, Riboflavin, Pyridoxine Hydrochloride, Niacinamide and D-Panthenol, for treatment of Non Specific Vaginitis (Bacterial Vaginitis ) the dose being lee - 2cc alternate 3 days.
2. The Use of Injection Vitamin B Complex, as claimed in No. 1, to inhibit excessive production of yeast in the vagina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KEKE/P/2003/00398 | 2003-11-17 | ||
| KE39803 | 2003-11-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2005046695A1 true WO2005046695A1 (en) | 2005-05-26 |
Family
ID=34587753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KE2004/000008 WO2005046695A1 (en) | 2003-11-17 | 2004-02-18 | Injection vitamin b complex for treatment of non specific vaginitis (bacterial vaginitis) |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2005046695A1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5821618A (en) * | 1981-07-31 | 1983-02-08 | Sankyo Co Ltd | Immunoregulator composed of vitamin b composition |
| WO1998042188A1 (en) * | 1997-03-26 | 1998-10-01 | Meryl Squires | Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases |
-
2004
- 2004-02-18 WO PCT/KE2004/000008 patent/WO2005046695A1/en active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5821618A (en) * | 1981-07-31 | 1983-02-08 | Sankyo Co Ltd | Immunoregulator composed of vitamin b composition |
| WO1998042188A1 (en) * | 1997-03-26 | 1998-10-01 | Meryl Squires | Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases |
Non-Patent Citations (1)
| Title |
|---|
| FRIEDLANDER A. ET AL: "Lactobacillus acidophillus and vitamin B complex in te treatment of vaginal infection", PANMINERVA MEDICA, vol. 28, 1986, pages 51 - 53 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101175503B (en) | Composition and method for regulating and remaining vaginal flora and vaginal acidity be normal | |
| WO1999026636A1 (en) | Pharmaceutical formulation for stimulating the growth of gram-positive bacilli and increasing the acidity in vagina and the use thereof | |
| JP2004529935A (en) | Composition comprising an antifungal agent for treating vulvar vaginitis and vaginosis | |
| CN102123736A (en) | Antimycotic and prebiotic pharmaceutical composition and a method for treating candidal vaginitis | |
| CN114588253B (en) | Pharmaceutical composition for repairing and preventing vaginal mucosa aging and preparation thereof | |
| Durfee et al. | Ineffectiveness of erythromycin for treatment of Haemophilus vaginalis-associated vaginitis: possible relationship to acidity of vaginal secretions | |
| RU2327486C1 (en) | Immunomodulating, antiviral, antibacterial, antioxidating, membrane stabilising, anti-inflammatory, antitoxic medicinal agent for inflammatory-infectious diseases | |
| EP3324938B1 (en) | Topical formulations and treatments | |
| WO2005046695A1 (en) | Injection vitamin b complex for treatment of non specific vaginitis (bacterial vaginitis) | |
| Brincker | Treatment of oral candidiasis in debilitated patients with miconazole—a new potent antifungal drug | |
| EP1051162B1 (en) | Methods and kits for treating vulvovaginal candidiasis with miconazole nitrate | |
| US20040138174A1 (en) | Use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for treating cervical erosion | |
| Sanz et al. | Randomized comparative trial of three regimens of itraconazole for treatment of vaginal mycoses | |
| WO2004016245A1 (en) | Optimal volume of intra-vaginal semisolid dosage forms for treating vaginal infections | |
| Cohen | Single dose treatment of vaginal candidosis: comparison of clotrimazole and isoconazole. | |
| Regidor et al. | Treatment and prevention of trichomoniasis, bacterial vaginosis and candidiasis with a new 7-day regime containing metronidazole and miconazole in a single vaginal pessary | |
| CN102652752A (en) | Drug composition for treating senile vaginitis and preparation method thereof | |
| US7705011B2 (en) | Agent for treatment and prevention of endometriosos and uterine adenomyosis | |
| EP1666046A1 (en) | Use of n-acetyl-d-aminoglycosamine in preparation of drugs for the treatment of cacer and metastasis | |
| EP1712229B1 (en) | Fluconazole-tinidazole combination for the treatment of vaginal infections, composition thereof and preparation and use of same | |
| CN103127490A (en) | Medicinal composition for treating vulvovaginal candidiasis | |
| US20210401806A1 (en) | Compositions and methods for treatment of vaginal infections | |
| CN117442545A (en) | Intravaginal drug delivery system based on maltodextrin and application thereof in treating vaginitis | |
| Kobayashi et al. | Results of a Clinical Investigation of Clotrimazole (Canesten), A New Anti-Mycotic Substance, in the Therapy of Vaginal Fungal Infections | |
| Panja | Treatment of trichomoniasis with metronidazole rectal suppositories |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
| 122 | Ep: pct application non-entry in european phase |